KisoJi Biotechnology Inc.

About KisoJi Biotechnology Inc.

KisoJi Biotechnology Inc. is a leading next-generation antibody company focused on discovering and developing highly differentiated antibody therapeutics for oncology and other diseases. Their mission is to create breakthrough therapeutics using an innovative antibody platform that visualizes the complete immune response for therapeutic, diagnostic, and vaccine development.

Products & Services

Antibody Platform:A proprietary platform built on single domain antibodies from multi-species transgenic mice, AI-enabled fingerprinting technology, and the creation of robust, manufacturable multi-specific antibodies.

Lead Program (TROP2 Antibody):A novel TROP2 antibody with robust therapeutic activity without the need for a drug conjugate.

Pipeline of Multi-Specific Antibodies:A pipeline of novel multi-specific antibodies with multiple mechanisms of action for various indications.

Specialties

Antibody Therapeutics Oncology AI-Enabled Antibody Fingerprinting Multi-Specific Antibodies Single Domain Antibodies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity T: - FT: Equity	A: 41000000 MR: - FA: $41 million FAN: 41000000	D: 2024-12-02 FD: 2024-12-02	5 investors

Equity Latest

2024-12-02

$41.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

H

Hua Gu

Scientific Advisor

K

Klaus Rajewsky

I

Irene Diamond

M

Marina Konopleva

Scientific Advisor

F

Frances King Black

S

Serge Muyldermans

Scientific Advisor

View 13 more team members with Pro

Unlock Full Team Directory

Recent News